Fully Human Single Domain Antibody Development Pipeline

At Protheragen, we are actively pursuing collaboration opportunities to license our innovative GeniusAb™ fully human single domain antibody (sdAb) platform or engage in co-development of fully human sdAb drug candidates. By harnessing the unique advantages of sdAbs, our objective is to develop antibody drug candidates with exceptional affinity and specificity, expediting the exploration and advancement of novel therapeutics.

If you are interested in any of the projects, please contact us for further discussion. We look forward to our collaboration.